Besremi
Named-patient access overview. Besremi is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
Quick orientation
Besremi (ropeginterferon alfa-2b-njft) is a long-acting monopegylated interferon alfa-2b developed by PharmaEssentia. The US Food and Drug Administration approved Besremi in November 2021 for the treatment of adults with polycythemia vera, a chronic myeloproliferative neoplasm. The drug is administered as a subcutaneous injection every two weeks during titration, with maintenance dosing typically extended to every four weeks once a stable haematologic response is achieved. Treatment is initiated and monitored by a haematologist with myeloproliferative neoplasm expertise; structured mental-health screening (including depression and suicidality assessment) is required because interferon-class therapy carries neuropsychiatric warnings.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
How Reserve Meds coordinates Besremi
- Patient or treating physician submits an intake at the patient portal.
- Reserve Meds clinical team verifies appropriateness for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific named-patient documentation is prepared.
- Besremi is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy with appropriate handling.
Access by country
Reserve Meds publishes a detailed country deep-dive for Besremi in every market we coordinate. Each page below covers the destination-country regulatory pathway, real costs, indicative timelines, physician-credential requirements, and handling notes. Tap any country to read the full deep-dive.
Start a request for Besremi
Submit a 60-second intake. The clinical team will follow up within 24 hours with case-specific feasibility, timeline, and a formal quote.
Frequently asked questions
How can I get Besremi if it is not approved or available in my country?
Reserve Meds coordinates US-sourced Besremi for patients through a physician-led, named-patient cross-border pathway. Your treating physician provides the prescription and clinical justification; Reserve Meds prepares the named-patient documentation for your country and arranges DSCSA-compliant US sourcing and delivery to your physician or hospital pharmacy.
Can I access Besremi through named-patient or compassionate-use import?
Yes. Named-patient access (also called compassionate use or personal import) is the core route Reserve Meds operates for Besremi. Eligibility and paperwork depend on the regulator in your country, and Reserve Meds maps the specific pathway for each market it coordinates.
Do I need a prescription to access Besremi through Reserve Meds?
Yes. Reserve Meds is not a pharmacy and does not prescribe. A valid prescription and clinical justification from your treating physician are required, and all clinical decisions remain with your physician.
How does Reserve Meds deliver Besremi to a patient?
Reserve Meds sources Besremi from a DSCSA-compliant US specialty supplier with full traceability and coordinates delivery to your treating physician or hospital pharmacy, with appropriate handling for the product.
How long does it take, and what does Besremi cost through Reserve Meds?
After a short intake, the clinical team responds within one business day with case-specific feasibility, an indicative timeline, and a formal written quote. Cost depends on the destination, the prescribed regimen, and the duration of therapy, and is confirmed in writing before anything proceeds.
How do I start a request for Besremi?
Submit a 60-second intake through the Reserve Meds patient portal, or message the concierge team on WhatsApp. A named coordinator follows up within 24 hours.